ATLAS
- 3,491 participants
- 10 sites in New Zealand
The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower cardiovascular events in addition to Aspirin with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome)
A Randomised, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and Thienopyridine in Subjects with Acute Coronary Syndromes
This is a phase II randomised, multicentre, double-blind, placebo-controlled study involving the use of an investigational drug Rivaroxaban. The purpose of this study is to evaluate the safety and efficacy of rivaroxaban and to determine what dose of rivaroxaban works the best for reducing blood clotting in the heart artery in participants with recent heart attack or unstable angina who are receiving background low dose-aspirin therapy.